

COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against omicron

Nungruthai Suntronwong^a, Ritthideach Yorsaeng^a, Jiratchaya Puenpa^a, Chompoonut Auphimai^a, Thanunrat Thongmee^a, Preeyaporn Vichaiwattana^a, Sitthichai Kanokudom^a, Thaneeya Duangchinda^b, Warangkana Chantima^{c,d}, Pattarakul Pakchotanon^b, Suvichada Assawakosri^a, Pornjarim Nilyanimit^a, Sirapa Klinfueng^a, Lakkhana Wongsrisang^a, Donchida Srimuan^a, Thaksaporn Thatsanatorn^a, Natthinee Sudhinaraset^a, Nasamon Wanlapakorn^a, Yong Poovorawan^{a,e}*

^aCenter of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

^bMolecular Biology of Dengue and Flaviviruses Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Development Agency, NSTDA, Pathum Thani 12120, Thailand

^cDivision of Dengue Hemorrhagic Fever Research, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

^dSiriraj Center of Research Excellence in Dengue and Emerging Pathogens, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

^eRoyal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand

*Corresponding author: Yong Poovorawan, MD

Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Email: yong.p@chula.ac.th

1 **COVID-19 breakthrough infection after inactivated vaccine induced robust**
2 **antibody responses and cross-neutralization of SARS-CoV-2 variants, but**
3 **less immunity against omicron**

4
5 **Abstract**

6 The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
7 and the waning of immunity in vaccinated individuals is resulting in increased numbers of
8 SARS-CoV-2 breakthrough infections. This study investigated binding antibody responses
9 and neutralizing activities against SARS-CoV-2 variants in patients with COVID-19 who had
10 been fully vaccinated with CoronaVac ($n = 78$), individuals who had been fully vaccinated
11 with CoronaVac but had not contracted COVID-19 ($n = 170$), and individuals who had
12 received AZD1222 as a third vaccination ($n = 210$). Breakthrough infection was generally
13 detected approximately 88 days after the second CoronaVac vaccination (interquartile range
14 68–100) days. Blood samples were collected at median of 34 days after infection. Binding
15 antibody levels in sera from patients with breakthrough infection were significantly higher
16 than those in individuals who had received AZD1222 as a third vaccination. However,
17 neutralizing activities against wild-type and variants including alpha (B.1.1.7), beta
18 (B.1.351), and delta (B.1.617.2) were comparable in patients with breakthrough infections
19 and individuals who received a third vaccination with AZD1222, which activities are
20 exceeding 90%. Omicron (B.1.1.529) was neutralized less effectively by serum from
21 breakthrough infection patients, with a 6.3-fold reduction compared to delta variants. The
22 study suggests that breakthrough infection after two doses of an inactivated vaccine can
23 induce neutralizing antibody against omicron. Further investigation is needed to assess the
24 long-term persistence of antibody against omicron variant.

25
26 **Keywords:** breakthrough, infection, SARS-CoV-2, omicron

27
28 Since the commencement of the coronavirus disease 2019 (COVID-19) outbreak at the
29 end of 2019, there have been more than 313 million cases of infection [1]. Vaccines are an
30 available tool to prevent and control this threat. Reduced viral susceptibility to
31 vaccine-induced antibodies due to the emergence of severe acute respiratory syndrome
32 coronavirus 2 (SARS-CoV-2) variants, together with the waning of vaccine-induced
33 immunity, is increasing the incidence of COVID-19 breakthrough infection after

34 vaccination [2,3]. Notably however, the study of immunogenicity and neutralization of
35 SARS-CoV-2 variants, particularly omicron (B.1.1.529), is limited [4]. This study aims to
36 determine antibody levels and cross-neutralization in patients with SARS-CoV-2
37 breakthrough infection following two doses of CoronaVac compared with those in uninfected
38 individuals who received two doses of CoronaVac and those who received AZD1222 as third
39 vaccination.

40

41 Patients who had been completely vaccinated with two doses of CoronaVac then
42 subsequently became infected with SARS-CoV-2 as determined via a positive polymerase
43 chain reaction (PCR) test were recruited at the Center of Excellence in Clinical Virology
44 between 21 April and 20 September, 2021. The SARS-CoV-2 variants circulating in Thailand
45 during the study period were alpha (April to June) and delta (July to September) (Figure 1).
46 Controls were unexposed SARS-CoV-2 individuals who had been fully vaccinated with two
47 doses of CoronaVac and screened with anti-nucleocapsid IgG as previously described [5].
48 Fully vaccinated CoronaVac individuals who received AZD1222 as a third vaccination were
49 also analysed [6].

50

51 All sera were tested for SARS-CoV-2-specific binding antibody responses via
52 enzyme-linked immunosorbent assays, including total immunoglobulin (Ig) against the
53 SARS-CoV-2 receptor-binding domain (RBD), and IgG and IgA specific for SARS-CoV-2
54 protein. Neutralizing activity against wild-type SARS-CoV-2 and variants including alpha
55 (B.1.1.7; N501Y), beta (B.1.351; K417N, E484K, and N501Y), and delta (B.1.617.2; L452R
56 and T478K) was assessed using a cPassTM SAR-CoV-2 neutralizing antibody detection kit
57 (GenScript, Jiangsu, China) in accordance with the manufacturer's instructions. Neutralizing
58 antibody titres against delta (B.1.617.2) and omicron (B.1.1.529) were determined using the
59 focus reduction neutralization test as previously described [7].

60

61 Geometric mean antibody titres with 95% confidence intervals (CIs) were calculated, and
62 neutralizing activities were expressed as medians and interquartile ranges (IQRs). Differences
63 were assessed using the Kruskal-Wallis method with Dunn's correction. GraphPad Prism was
64 used to generate figures, and statistics were analysed using SPSS. Statistical significance was
65 defined as $p < 0.05$. The study protocol was conducted in accordance with the Declaration of
66 Helsinki and Good Clinical Practice principles, and it was approved by the Research Ethics
67 Committee of the Faculty of Medicine, Chulalongkorn University (IRB numbers 835/64,
192/64, and 546/64). All participants provided written informed consent.

67

68 The group who had been vaccinated with two doses of CoronaVac and subsequently
69 became infected with SARS-CoV-2 contained 78 patients with a mean age of 34.2 years; 58
70 women (74.4%) and 20 men (25.6%). The median time between the second CoronaVac
71 vaccination and breakthrough infection was 88 days (IQR 68–100 days). Blood samples were
72 collected at 34 days (IQR 29–43) post infection. The group who had been fully vaccinated
73 with CoronaVac but remained unexposed to SARS-CoV-2 infection contained 170
74 participants with a mean age of 42.3 years; 89 women (52.4%) and 81 men (47.6%). The
75 blood samples were collected at median of 29 days (IQR 27–31) post a second dose
76 vaccination. The group who had been fully vaccinated with CoronaVac then received
77 AZD1222 as a third vaccination contained 210 participants with a mean age of 40 years; 151
78 women (71.9%) and 59 men (28.1%). The median time between blood sampling and a third
79 dose was 28 days (IQR 20–32) (Supplementary Table 1).

80 Total RBD-specific Ig was significantly increased in patients with breakthrough infection
81 (18154 units per millilitre (U/mL); 95% CI 13506–24402 U/mL) compared to fully
82 vaccinated individuals without infection (98 U/mL; 95% CI 83–116 U/mL) (Figure 1A).
83 RBD-specific Ig was higher in participants with breakthrough infection than in those who
84 received AZD1222 as a third vaccination (7947 U/mL; 95% CI 7277–8679). Anti-RBD IgG
85 was significantly higher in patients with breakthrough infection (3668 binding antibody units
86 per millilitre (BAU)/mL; 95% CI 2802–4802 BAU/mL) compared to fully vaccinated
87 individuals (128 BAU/mL, 95% CI 114–144 BAU/mL) and those who received AZD1222 as
88 a third vaccination (1492 BAU/mL, 95% CI 1367–1629 BAU/mL) (Figure 1B). Moreover,
89 individuals with breakthrough infection (76/78; 97.4%) and those who received AZD1222 as
90 a third vaccination (54/55; 98.2) were seropositive for anti-S1 IgA. Conversely, only 22/51
91 (43.1%) of uninfected individuals who had been fully vaccinated with CoronaVac exhibited
92 seropositivity for anti-S1 IgA (Figure 1C). These results indicate that patients with
93 breakthrough infection could mount SARS-CoV-2-specific binding antibody responses.

94 Among breakthrough infection patients, 77/78 (98.7%) exhibited potential neutralization
95 determined using sVNT against wild-type and SARS-CoV-2 variants. The median
96 neutralizing activities in patients with breakthrough infection were 97.5% for wild-type,
97 97.7% for alpha, 95.6% for beta, and 97.9% for delta (Supplementary Table 2). Neutralizing
98 activities in breakthrough infection patients were significantly higher than those in unexposed
99 individuals following complete CoronaVac vaccination ($p < 0.001$) (Figure 1D–G).
100 Compared to individuals who received AZD1222 as a third vaccination, in patients with
101 breakthrough infection neutralizing activity was significantly higher for alpha ($p = 0.02$) and

102 beta ($p < 0.01$) variants, but not wild-type or delta variants. This suggests that variant cross-
103 neutralization was improved after breakthrough infection. With respect to neutralizing
104 antibody titres in sera from patients with breakthrough infection determined using live virus
105 neutralization test, FRNT50, the geometric mean titres against delta were 1332 (95% CI 875–
106 2026), whereas those against omicron were 212 (95% CI 142–316) (Figure 1H). This
107 indicates that omicron is less effectively neutralized by serum antibody derived from
108 breakthrough infection, with a 6.3-fold reduction compared to delta ($p < 0.001$).

109

110 Our findings indicate that patients with breakthrough infection exhibited potent antibody
111 responses, with both IgG and IgA titres exceeding those of individuals who received
112 AZD1222 as a third vaccination. Notably the levels of anti-RBD IgG in almost all
113 breakthrough patients were higher than 506 BAU/mL, which was the antibody level
114 associated with 80% effectiveness against symptomatic alpha variant infection in a previous
115 report [8]. Breakthrough infection increased neutralizing activity that cross-inhibited
116 SARS-CoV-2 variants corresponding to wild-type, alpha, beta, and delta. In a previous study
117 a similar result was observed in individuals who had received two mRNA SARS-CoV-2
118 vaccinations and subsequently became infected [9]. This indicates that natural immunity and
119 vaccine-induced immunity combined result in higher neutralizing potency than vaccination or
120 infection alone [10].

121 Omicron variants are reportedly less susceptible to neutralization by existing immunity
122 after natural infection [11], and vaccine-induced immunity [12]. Notably, sera from patients
123 with breakthrough infection in the present study also exhibited less neutralizing activity
124 against omicron than against delta. Consistent with a previous study [4] neutralization against
125 omicron was 11.7-fold less than that for wild-type, and 7.9-fold less than that for delta. These
126 results suggest immune escape of omicron in breakthrough infection patients. Reduced
127 neutralizing potency against the omicron variant may be associated with many mutations in
128 the spike protein [13].

129 The limitations of this study include a small sample size, and the SARS-CoV-2 variants
130 that caused breakthrough infections were not identified. Omicron neutralization assays were
131 not conducted using sera from unexposed individuals who had been fully vaccinated with two
132 doses of CoronaVac or those who received AZD1222 as a third vaccination. Our finding
133 highlights that breakthrough infection after two doses of inactivated vaccines can induce
134 neutralizing antibody against omicron. Further investigation is needed to assess the long-term
135 persistence of antibody against omicron variant.

136

137 **Acknowledgments**

138 This work was supported by the National Research Council of Thailand, the Health
139 Systems Research Institute, the Center of Excellence in Clinical Virology of
140 Chulalongkorn University, and King Chulalongkorn Memorial Hospital. National Center
141 for Genetic Engineering and Biotechnology (BIOTEC Platform No. P2051613). Nungruthai
142 Suntronwong reports that financial support was also provided by the Second Century Fund
143 Fellowship of Chulalongkorn University.

144

145 **Declaration of interest statement**

146 All authors have declared no competing interests.

147

148 **Data availability statement**

149 All data are available in the report. Additional information can be requested from the
150 corresponding author.


151

152 **References**

- 153 [1] World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Cited 2022
154 January 14th]. Available from: <https://covid19.who.int>.
- 155 [2] Mizrahi B, Lotan R, Kalkstein N, et al. Correlation of SARS-CoV-2-breakthrough
156 infections to time-from-vaccine. *Nat Commun.* 2021;12(1):1–5.
- 157 [3] Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated
158 health care workers. *N Engl J Med.* 2021;385(16):1474–1484.
- 159 [4] Ai J, Zhang H, Zhang Y, et al. Omicron variant showed lower neutralizing sensitivity than
160 other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. *Emerg Microbes
161 Infect.* 2021:1–24 (just-accepted). doi: 10.1080/22221751.2021.2022440.
- 162 [5] Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and
163 immunogenicity of heterologous and homologous inactivated and adenoviral-vectored
164 COVID-19 vaccines in healthy adults. *medRxiv.* 2021. doi:10.1101/2021.11.04.21265908
- 165 [6] Yorsaeng R, Suntronwong N, Phowatthanasathian H, et al. Immunogenicity of a third
166 dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in
167 healthy adults. *Vaccine.* 2021;40(3):524–530.
- 168 [7] Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7
169 variant by convalescent and vaccine sera. *Cell.* 2021;184(8):2201–2211.

- 170 [8] Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
171 asymptomatic SARS-CoV-2 infection. *Nat Med*. 2021;27(11):2032–2040.
- 172 [9] Bates TA, McBride SK, Winders B, et al. Antibody response and variant cross-
173 neutralization after SARS-CoV-2 breakthrough infection. *JAMA*. 2021. doi:
174 10.1001/jama.2021.22898.
- 175 [10] Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant
176 neutralizing antibodies elicited by SARS-CoV-2 infection. *Science*. 2021. doi:
177 10.1126/science.abg9175.
- 178 [11] Pulliam JR, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2
179 reinfection associated with emergence of the Omicron variant in South Africa. *medRxiv*.
180 2021. doi: 10.1101/2021.11.11.21266068.
- 181 [12] Roessler A, Riepler L, Bante D, et al. SARS-CoV-2 B. 1.1. 529 variant (Omicron)
182 evades neutralization by sera from vaccinated and convalescent individuals. *medRxiv*. 2021.
183 doi:10.1101/2021.12.08.21267491
- 184 [13] Sarkar R, Lo M, Saha R, et al. S glycoprotein diversity of the Omicron variant.
185 *MedRxiv*. 2021. doi: 10.1101/2021.12.04.21267284.

186 **Figure legends**



187

188

189 **Figure 1: SARS-CoV-2-specific binding antibody responses and neutralizing activities.**

190 Immune response of individuals with SARS-CoV-2 breakthrough infection (CV+CV+

191 Infection) was compared to those with fully vaccinated CoronaVac vaccines without infection

192 (CV+CV) and those who received AZD1222 as third booster (CV+CV+AZ). Serum anti-

193 RBD Ig activity (A), anti-RBD IgG binding antibody units (B), and anti-S1 IgA (optical

194 density of the sample divided by a calibrator; S/C ratio) (C). Neutralizing activities against

195 wild-type (D), B.1.1.7-alpha (E), B.1.351-beta (F), and B.1.617.2-delta (G). Neutralizing

196 antibody titres against B.1.617.2-delta and B.1.1.529-omicron in serum samples from

197 individuals with breakthrough infection determined using focus reduction neutralization test

198 50 values (H). Geometric mean titres with 95% CIs and median values with IQRs are shown

199 as horizontal bars. Dotted lines indicate cut-off values, and grey shaded areas depict values

200 under the cut-off. Statistics were calculated using Kruskal–Wallis tests with Dunn’s post hoc

201 correction. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.